FY results showed an adjusted net loss of £3.8m, with year-end cash of £2.5m – in line with the trading update at the time of the recent £14m placing. Near-term focus remains on the outcome of study SG016, and although the enrolment rate into the COVID-19 trial has slowed in recent weeks, with 98 out of the targeted 100 patients having been enrolled, top-line data is expected to be presented in July. The company also confirmed that the trial of SNG001 in COVID-19 patie
26 May 2020
Synairgen - FY 2019 results and COVID-19 trial update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - FY 2019 results and COVID-19 trial update
Synairgen plc (SNG:LON) | 6.8 0 0.0% | Mkt Cap: 13.6m
- Published:
26 May 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
11
FY results showed an adjusted net loss of £3.8m, with year-end cash of £2.5m – in line with the trading update at the time of the recent £14m placing. Near-term focus remains on the outcome of study SG016, and although the enrolment rate into the COVID-19 trial has slowed in recent weeks, with 98 out of the targeted 100 patients having been enrolled, top-line data is expected to be presented in July. The company also confirmed that the trial of SNG001 in COVID-19 patie